Silencing Lyn kinase overcomes resistance to imatinib in Bcr-Abl-dependent CML cells

被引：0
|
作者：
Wu, Ji Yuan [1 ]
Talpaz, Moshe [1 ]
Donato, Nicholas J. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
CANCER RESEARCH | 2006年 / 66卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2345
引用
收藏
页数：2
相关论文
共 50 条
  • [31] The significance of BCR-ABL dependent EpCAM expression for treatment resistance in CML
    Towhidi, T.
    Kaehler, M.
    Faehnrich, A.
    Osius, J.
    Zhuang, R.
    Britsemmer, J. H.
    Boddu, V. K.
    Gires, O.
    Busch, H.
    Illert, L.
    Duyster, J.
    Gemoll, T.
    Juecker, M.
    Gieseler, F.
    Kirchner, H.
    Casorbi, I.
    Gebauer, N.
    Hochhaus, A.
    Ernst, T.
    von Bubnoff, N.
    Gorantla, S. P.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 205 - 206
  • [32] Targeting SOS1 overcomes imatinib resistance with BCR-ABL independence through uptake transporter SLC22A4 in CML
    Liu, Yanjun
    Li, Chuting
    Su, Rui
    Yin, Zhao
    Huang, Guiping
    Yang, Juhua
    Li, Zhendong
    Zhang, Keda
    Fei, Jia
    MOLECULAR THERAPY-ONCOLYTICS, 2021, 23 : 560 - 570
  • [33] Spectrum of BCR-ABL Kinase Domain Mutations in North Macedonia in Patients With CML Resistant to Imatinib
    Stojanovska-Jakimovska, Simona
    Cvetanoski, Milche
    Ridova, Nevenka
    Trajkova, Sanja
    Popova-Labachevska, Marija
    Mojsovska, Tara
    Dukovski, Dushko
    Pivkova-Veljanovska, Aleksandra
    Stojanovski, Zlate
    Krstevska-Balkanov, Svetlana
    Pavkovic, Marica
    Chadievski, Lazar
    Panovska-Stavridis, Irina
    Ivanovski, Martin
    Gjorgievska, Emilija
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S375 - S375
  • [34] The HSP90 inhibitor KW-2478 depletes the malignancy of BCR/ABL and overcomes the imatinib-resistance caused by BCR/ABL amplification
    Dachuan Zeng
    Miao Gao
    Renren Zheng
    Run Qin
    Wei He
    Suotian Liu
    Wei Wei
    Zhenglan Huang
    Experimental Hematology & Oncology, 11
  • [35] The HSP90 inhibitor KW-2478 depletes the malignancy of BCR/ABL and overcomes the imatinib-resistance caused by BCR/ABL amplification
    Zeng, Dachuan
    Gao, Miao
    Zheng, Renren
    Qin, Run
    He, Wei
    Liu, Suotian
    Wei, Wei
    Huang, Zhenglan
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2022, 11 (01)
  • [36] Mebendazole effectively overcomes imatinib resistance by dual- targeting BCR/ABL oncoprotein and β-tubulin in chronic myeloid leukemia cells
    Yang, Li
    Du, Zhuanyun
    Peng, Yuhang
    Zhang, Wenyao
    Feng, Wenli
    Yuan, Ying
    KOREAN JOURNAL OF PHYSIOLOGY & PHARMACOLOGY, 2025, 29 (01): : 67 - 81
  • [37] STAT5 Is a Critical Component Of The Time-Dependent Sensitivity Of CML Cells To TKI Treatment In a Bcr-Abl-Dependent, But JAK2-Independent Manner
    Schafranek, Lisa
    Nievergall, Eva
    Powell, Jason A.
    Hiwase, Devendra K.
    White, Deborah L.
    Hughes, Timothy P.
    Leclercq, Tamara
    BLOOD, 2013, 122 (21)
  • [38] The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib
    J S Khorashad
    M Anand
    D Marin
    S Saunders
    T Al-Jabary
    A Iqbal
    S Margerison
    J V Melo
    J M Goldman
    J F Apperley
    J Kaeda
    Leukemia, 2006, 20 : 658 - 663
  • [39] The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib
    Khorashad, JS
    Anand, M
    Marin, D
    Sauders, S
    Al-Jabary, T
    Iqbal, A
    Margerison, S
    Melo, JV
    Goldman, JM
    Apperley, JF
    Kaeda, J
    LEUKEMIA, 2006, 20 (04) : 658 - 663
  • [40] Targeting Imatinib resistance: Progress toward "final generation" inhibitors of BCR-ABL for the treatment of CML
    Shakespeare, William
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2012, 244
12345